NBRV
Price:
$1.42
Market Cap:
$4.55M
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomye...[Read more]
Industry
Biotechnology
IPO Date
2017-06-23
Stock Exchange
NASDAQ
Ticker
NBRV
According to Nabriva Therapeutics plc’s latest financial reports and current stock price. The company's current ROE is -201.91%. This represents a change of 44.39% compared to the average of -139.84% of the last 4 quarters.
The mean historical ROE of Nabriva Therapeutics plc over the last ten years is -261.95%. The current -201.91% ROE has changed -22.92% with respect to the historical average. Over the past ten years (40 quarters), NBRV's ROE was at its highest in in the March 2023 quarter at 209.30%. The ROE was at its lowest in in the December 2022 quarter at -691.71%.
Average
-261.95%
Median
-91.65%
Minimum
-1736.56%
Maximum
44.36%
Discovering the peaks and valleys of Nabriva Therapeutics plc ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.77%
Maximum Annual ROE = 44.36%
Minimum Annual Increase = -166.61%
Minimum Annual ROE = -1736.56%
Year | ROE | Change |
---|---|---|
2022 | -1736.56% | 1.77% |
2021 | -92.69% | -55.80% |
2020 | -209.70% | 4.58% |
2019 | -200.52% | 19.90% |
2018 | -167.24% | 84.59% |
2017 | -90.60% | 27.52% |
2016 | -71.05% | 146.24% |
2015 | -28.85% | -165.04% |
2014 | 44.36% | -166.61% |
The current ROE of Nabriva Therapeutics plc (NBRV) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-679.65%
5-year avg
-481.34%
10-year avg
-261.95%
Nabriva Therapeutics plc’s ROE is greater than Evoke Pharma, Inc. (-308.51%), less than Trevena, Inc. (210.71%), greater than Diffusion Pharmaceuticals Inc. (-44.12%), less than Paratek Pharmaceuticals, Inc. (42.54%), less than Clearside Biomedical, Inc. (126.50%),
Company | ROE | Market cap |
---|---|---|
-308.51% | $7.28M | |
210.71% | $1.55M | |
-44.12% | $8.98M | |
42.54% | $127.83M | |
126.50% | $70.46M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Nabriva Therapeutics plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Nabriva Therapeutics plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Nabriva Therapeutics plc's ROE?
How is the ROE calculated for Nabriva Therapeutics plc (NBRV)?
What is the highest ROE for Nabriva Therapeutics plc (NBRV)?
What is the 3-year average ROE for Nabriva Therapeutics plc (NBRV)?
What is the 5-year average ROE for Nabriva Therapeutics plc (NBRV)?
How does the current ROE for Nabriva Therapeutics plc (NBRV) compare to its historical average?